Tetra Discusses Clinical Program in New Interview with CFN Media

SEATTLE, WA–(Marketwired – Feb 14, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing the progress made by Tetra Bio-Pharma Inc. ( OTC PINK : GRPOF ) ( CNSX : TBP ) in its clinical trial program. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.

Medical marijuana may be legal for roughly 60% of the U.S. population, but the cost of the drug remains prohibitive for many patients in need. Tetra Bio-Pharma aims to undergo FDA-sanctioned clinical trials for dried medical marijuana to secure prescription drug coverage from insurance companies.

Tetra Bio-Pharma held a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in late January to advance

... read more at: http://finance.yahoo.com/news/tetra-discusses-clinical-program-interview-140000592.html

by